Innovative models for in vitro detection of seizure. Toxicology Research 8 (6), 784-788.
Data show that toxicity to the central nervous system (CNS) is the most frequent cause of safety failures during the clinical phase of drug development. CNS endpoints such as seizure pose a safety risk to patients and volunteers and can lead to a loss of competitiveness, delays, and increased costs. Current methods rely on detection in the nonclinical rodent and non-rodent studies required to support clinical trials. There are two main issues with this approach; seizure may be missed in the animal studies and, even if seizure is detected, significant resource has already been invested in the project by this stage…
By Chloe Atkinson|2022-11-28T14:08:29+00:00June 17th, 2021|Comments Off on Innovative models for in vitro detection of seizure. Toxicology Research 8 (6), 784-788.